clinical trial · NCT07059091
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Chronic Obstructive Pulmonary Disease (COPD)AllergiesOmalizumab (Xolair®)Sodium Chloride (NaCl) 0.9 %
brief summary
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
started
Feb 12, 2026
primary completion
Jan 1, 2031
completion
May 1, 2031
last updated
Feb 17, 2026
detailed description
This study is for people 40 years and older with COPD who also have allergens in their home that they are allergic to, like pet dander, cockroaches or dust mites.
official title
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol